firstwordpharmaMarch 15, 2019
Tag: Matinas BioPharma , Common Stock , Proposed Public Offering
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering are to be sold by Matinas BioPharma. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.
BTIG, LLC is acting as sole book-running manager for the offering.
Matinas BioPharma anticipates using the net proceeds from the offering primarily for ongoing development activities for its product candidates, namely MAT9001, and its lipid nano-crystal ("LNC") platform delivery technology and for working capital and other general corporate purposes.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was declared effective by the Securities and Exchange Commission (the "SEC") on April 12, 2017. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. Before you invest, you should read the preliminary prospectus supplement and accompanying base prospectus for more complete information about Matinas BioPharma and this offering. An electronic copy of the preliminary prospectus supplement and accompanying base prospectus relating to the offering, when filed, will be available on the SEC's website at www.sec.gov and may also be obtained, when available, by contacting BTIG, LLC, at 825 Third Avenue, 6th Floor, New York, NY, 10022, or by telephone at (212) 593-7555 or by e-mail at equitycapitalmarkets@btig.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Register as Visitor to CPhI China 2019!
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: